Although a survival benefit has been demonstrated for carriers of P/LP variants in BRCA1 undergoing either IBS or RRM, with RRM being associated with significantly lower breast cancer-specific mortality (Heemskerk-Gerritsen et al. 2019; Lubinski et al. 2024), the choice between IBS or RRM is based on the carrier’s preferences and beliefs. The gene discussed is BRCA1; the disease is irritable bowel syndrome.